Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted Therapies

[Image: see text] Inhibition of the androgen receptor (AR) is the mainstay treatment for advanced prostate cancer. Ralaniten (formally EPI-002) prevents AR transcriptional activity by binding to its N-terminal domain (NTD) which is essential for transcriptional activity. Ralaniten acetate (EPI-506)...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:ACS Pharmacol Transl Sci
Asıl Yazarlar: Obst, Jon K., Wang, Jun, Jian, Kunzhong, Williams, David E., Tien, Amy H., Mawji, Nasrin, Tam, Teresa, Yang, Yu Chi, Andersen, Raymond J., Chi, Kim N., Montgomery, Bruce, Sadar, Marianne D.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Chemical Society 2019
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7088963/
https://ncbi.nlm.nih.gov/pubmed/32259077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsptsci.9b00065
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller